Format

Send to

Choose Destination
Intern Med J. 2018 Jun;48(6):724-727. doi: 10.1111/imj.13814.

Rituximab treatment in primary angiitis of the central nervous system.

Author information

1
Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia.
2
Department of Medicine, The University of Melbourne at St Vincent's Hospital, Melbourne, Victoria, Australia.

Abstract

Primary angiitis of the central nervous system (PACNS) is a rare autoimmune vasculitis affecting the brain and spinal cord. Treatment with biological agents has revolutionised the treatment of many rheumatic conditions but there is scant literature regarding the use of biological agents in PACNS. We present three cases of PACNS treated with rituximab, including two cases of relapsed disease, and a literature review suggesting a role for rituximab in this condition.

KEYWORDS:

primary angiitis of the central nervous system; rituximab; vasculitis

PMID:
29898271
DOI:
10.1111/imj.13814
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center